Some info from Lincoln Pharma Annual report, as well as from Screener.
●Growth in sales/ PAT every year
● Exports growth from 25.5% ( 2013 ) to 57.5% this year
Uploading: Screenshot_20230906_184801_Drive.jpg…
● Aim to expand network to 90+ countries from current 60.
Uploading: Screenshot_20230906_185522_Drive.jpg…
Target to achieve 750 Cr. Topline with better margins by FY26
Uploading: Screenshot_20230906_185917_Drive.jpg…
● About 60 Cr. Capex in last 2 year
● CFO FY23: 68 Cr. Vs 99 Cr. last year - increase in receivables
● Debt free,
Mutualfund/ cash/ Equivalents of about 200 Cr.
Screener data: Lincoln pharma traded at
PE of 20-22( FY '12,'15 &'18 peak) Current PE=13
FY’26 guidance: 750 Cr sales.
with operating leverage, they may get to 125-150 Cr PAT
Current Mcap: 1000 Cr.
If it reaches to its peak valuation in PE terms? In that case, it may get to 2500-3000 Cr. Mcap. by that time ( FY 26 )
Possible?
Disc: Invested, biased view.
I am not sebi registered. Do your own research
| Subscribe To Our Free Newsletter |
